Afatinib for erlotinib refractory brain metastases in a patient with EGFR-mutant non-small-cell lung cancer: Can high-affinity TKI substitute for high-dose TKI?

Journal of Thoracic Oncology

Volumn 10, Issue 7, 2015, Pages e65-e66

  Hata, Akito ^a   Katakami, Nobuyuki ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

AGED; BRAIN METASTASIS; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; GENE MUTATION; HUMAN; LETTER; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84942909870     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000479     Document Type: Letter

References (5)

1. Hoffknecht P, Tufman A, Wehler T, Efficacy of the irreversible erbb family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 2014. [Epub ahead of print].
2. Hata A, Katakami N, Kaji R, Fujita S, Imai Y, Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 2013 8 e27 e29
3. Jackman DM, Holmes AJ, Lindeman N, Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006 24 4517 4520
4. Hata A, Kaji R, Fujita S, Katakami N, High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol 2011 6 653 654
5. Jackman DM, Mach SL, Heng JC, Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2013 31 (suppl; abstr 8116)